公开(公告)号：US11865100B2

公开(公告)日：2024-01-09

申请号：US17154689

申请日：2021-01-21

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.

公开(公告)号：US11877997B2

公开(公告)日：2024-01-23

申请号：US17156941

申请日：2021-01-25

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.

公开(公告)号：US10945987B2

公开(公告)日：2021-03-16

申请号：US16794734

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.

公开(公告)号：US11426378B2

公开(公告)日：2022-08-30

申请号：US16794887

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/107 ,  A61K9/00 ,  A61K9/06 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.

公开(公告)号：US10933046B2

公开(公告)日：2021-03-02

申请号：US16794839

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.